Press releases
-
-
New Headway Report shows that increased investment in mental health care can avoid costs of more than €122 billion across Europe
The report highlights the significant burden that mental health conditions place on European societies and healthcare systems.
-
Angelini Pharma presents long-term data for cenobamate demonstrating sustained benefit in adults living with Epilepsy
Angelini Pharma today shared positive findings from its clinical trials in epilepsy.
-
Angelini Pharma launches new crowd-sourcing challenge to fund innovative solutions to drug adherence and management of epilepsy
Angelini Pharma will award 25,000 $, with the potential of further awards not less than $5,000.
-
Angelini Pharma and SK Biopharmaceuticals announce treatment of more than 100,000 patients globally with Innovative Anti-Seizure Medication Cenobamate
Milestone coincides with expansion of cenobamate access to more than 100 markets worldwide
-
New Headway Report
Eco-anxiety, characterized by a pervasive fear of climate change and its consequences, has emerged as a significant concern for mental health, particularly among young people.
-
-
Announced today the publication of the second edition of the Headway – A new roadmap in Brain Health: Focus Epilepsy Report
The report shows up to 40% of European patients living with epilepsy are receiving inadequate treatment to control seizures.
-
Angelini Pharma launches LIFE-GREENAPI as part of its green transition strategy
LIFE-GREENAPI will deploy a more efficient, greener, and innovative process for producing Active Pharmaceutical Ingredients (APIs), by switching from batch to flow chemistry technology.
-
